CAPN9

Calpain-9 · O14815 · CAPN9 on Sugi Atlas →

2,018 patent compounds predicted against CAPN9, 1,300 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8219586 SCHEMBL8219586 0.81 3/20
SCHEMBL4777829 SCHEMBL4777829 0.79 3/20
SCHEMBL7297722 SCHEMBL7297722 0.77 3/20
SCHEMBL7306078 SCHEMBL7306078 0.77 3/20
SCHEMBL7298531 SCHEMBL7298531 0.73 3/20
SCHEMBL7305468 SCHEMBL7305468 0.73 3/20
Aloxistatin Aloxistatin (SCHEMBL254426) 0.72 3/20
Aloxistatin Aloxistatin (SCHEMBL483320) 0.72 3/20
SCHEMBL7300861 SCHEMBL7300861 0.64 3/20
Aloxistatin Aloxistatin (SCHEMBL9314220) 0.64 3/20
SCHEMBL7364463 SCHEMBL7364463 0.63 3/20
SCHEMBL1804811 SCHEMBL1804811 0.60 3/20
Formic Acid Formic Acid (SCHEMBL7305237) 0.57 3/20
SCHEMBL4777823 SCHEMBL4777823 0.56 3/20
SCHEMBL7302942 SCHEMBL7302942 0.56 3/20
SCHEMBL7364469 SCHEMBL7364469 0.55 3/20
SCHEMBL7300867 SCHEMBL7300867 0.55 3/20
Formic Acid Formic Acid (SCHEMBL7299223) 0.54 3/20
SCHEMBL7404688 SCHEMBL7404688 0.54 3/20
SCHEMBL7359662 SCHEMBL7359662 0.53 3/20

Clinical trials — most relevant to CAPN9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy PHASE2/PHASE3COMPLETED
Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival PHASE1UNKNOWN
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies nanUNKNOWN
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease nanCOMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
LGMD R1 Natural History Study nanACTIVE_NOT_RECRUITING
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study nanRECRUITING
Circulating Markers for Ischemic Heart Disease nanRECRUITING
Congenital Muscle Disease Study of Patient and Family Reported Medical Information nanRECRUITING
Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis nanUNKNOWN
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD nanENROLLING_BY_INVITATION
Evolution of the Functional and Muscular State of Patients With Muscular Dystrophy 2A Belts nanACTIVE_NOT_RECRUITING
Genetics of Familial and Sporadic ALS nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Pediatric Cardiomyopathy Mutation Analysis nanRECRUITING
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program nanCOMPLETED
Blood-based Biomarkers for the Prognosis of Sports Related Concussion nanCOMPLETED
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure nanRECRUITING
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests nanUNKNOWN
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures nanRECRUITING
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases nanCOMPLETED
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis nanCOMPLETED
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CAPN9 binder may also engage these)

ProteinNameSimilarity
Q92178 1.000 Q92178 →
Q07009 1.000 Q07009 →
Q9D805 1.000 Q9D805 →
CAPN2 Calpain-2 catalytic subunit 1.000 landscape →
O08529 1.000 O08529 →
P00789 1.000 P00789 →
Q9GLG1 1.000 Q9GLG1 →
Q27971 1.000 Q27971 →
Q91VA3 1.000 Q91VA3 →
A6NHC0 1.000 A6NHC0 →
Q9GLG2 1.000 Q9GLG2 →
P97571 1.000 P97571 →
P35750 1.000 P35750 →
O35920 1.000 O35920 →
Q78EJ9 1.000 Q78EJ9 →
Q5NVS7 0.999 Q5NVS7 →
CAPN1 Calpain-1 catalytic subunit 0.999 landscape →
Q9TTH8 0.999 Q9TTH8 →
O35350 0.999 O35350 →
Q27970 0.999 Q27970 →
P20807 0.998 P20807 →
Q64691 0.998 Q64691 →
P16259 0.997 P16259 →
Q6J756 0.997 Q6J756 →
Q9GLG7 0.996 Q9GLG7 →
P43368 0.996 P43368 →
P06814 0.995 P06814 →
Q11002 0.995 Q11002 →
Q9UMQ6 0.994 Q9UMQ6 →
Q4V8Q1 0.994 Q4V8Q1 →